论文部分内容阅读
目的:观察美托洛尔联合尼群地平治疗原发性高血压的临床效果。方法:将我院2008年1月-2010年6月收治的120例原发性高血压患者随机均分为对照组和观察组。对照组口服美托洛尔50mg,bid;观察组口服美托洛尔12.5mg,tid+尼群地平10mg,tid。治疗后,将2组患者的总有效率、不良反应发生率及治疗前后的心肌肥厚情况、血脂水平进行统计、比较。结果:观察组的治疗总有效率高于对照组(100.0%vs.93.3%,P<0.05),不良反应发生率低于对照组(5.0%vs.15.0%,P<0.05),治疗后观察组的心肌肥厚改善程度及血清甘油三酯(TG)、载脂蛋白B100(APO-B100)及低密度脂蛋白胆固醇(LDL-C)均低于对照组(P<0.05),而总胆固醇(TC)及高密度脂蛋白胆固醇(HDL-C)比较,则差异均无统计学意义(P>0.05)。结论:美托洛尔联合尼群地平可有效治疗原发性高血压,不良反应少,并能有效改善心肌肥厚程度及TG、APO-B100、LDL-C水平。
Objective: To observe the clinical effect of metoprolol combined with nitrendipine in the treatment of essential hypertension. Methods: A total of 120 patients with essential hypertension admitted to our hospital from January 2008 to June 2010 were randomly divided into control group and observation group. The control group was treated with metoprolol 50mg bid; the observation group was given metoprolol 12.5mg and tid + nitrendipine 10mg tid. After treatment, the two groups of patients with total effective rate, the incidence of adverse reactions and before and after treatment of cardiac hypertrophy, blood lipid levels were statistically compared. Results: The total effective rate of the observation group was higher than that of the control group (100.0% vs 93.3%, P <0.05), and the incidence of adverse reactions was lower than that of the control group (5.0% vs.15.0%, P <0.05) The improvement of myocardial hypertrophy and serum triglyceride (TG), apolipoprotein B100 (APO-B100) and low density lipoprotein cholesterol (LDL-C) were lower than those of the control group (P <0.05) TC) and high-density lipoprotein cholesterol (HDL-C), the difference was not statistically significant (P> 0.05). Conclusion: Metoprolol combined with nitrendipine can effectively treat essential hypertension with less adverse reactions and can effectively improve the level of myocardial hypertrophy and the levels of TG, APO-B100 and LDL-C.